Brains Bioceutical Corp. completes a USD $31.9 Million Capital Raise with Lead Investor DSM Venturing

CANNANNEW REPORT

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (“Brains” or the “Company”) is pleased to announce the completion of a USD $31.9 million capital raise with DSM Venturing and existing Brains shareholders. DSM Venturing, who acted as lead investor in this round, is the corporate venture arm of Royal DSM (“DSM”), a global, purpose led science-based company active in health, nutrition and sustainable living. This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Del Morgan & Co. acted as Brains’ financial agent in respect to the capital raise. “The completion of the capital raise marks an exciting milestone for the Brains’ team. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar. “The growing demand for isolated CBD Active Pharmaceutical Ingredients (API’s) within the pharmaceutical and nutraceutical industry continues to expand. Our team has worked tirelessly to position Brains as the market leader within the CBD industry. Our suite of licences has allowed Brains to scale rapidly within the industry,” Brar continued. Pieter Wolters, Managing Director DSM Venturing, commented: “The CBD market is fast-growing, powered by increasingly strong scientific evidence that demonstrate the potential of CBD API’s in a number of therapeutic areas. Also, consumers increasingly turn to CBD’s to address health issues. Brains unparalleled expertise and manufacturing capabilities in the CBD space combined with DSM’s unique scientific and marketing capabilities in the pharmaceutical sector make this the ideal partnership to help pharmaceutical players realizing the potential of CBD’s for early stage drug development.’’   Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. It…

Excerpt only …
READ MORE BELOW
Source : Brains Bioceutical Corp. completes a USD .9 Million Capital Raise with Lead Investor DSM Venturing

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.